GlobeImmune (GBIM) Takes Upward Bounce; Smith & Wesson (SWHC), Sturm Ruger (RGR) Surging on Orlando Shooting Concerns

GlobeImmune_GBIM

The price of GlobeImmune Inc. (Nasdaq:GBIM) stock soared to touch the $2.41 mark in early trade Monday, currently changing hands at $1.93, up $0.71 (or +58.20%) with 5,967,438 shares traded so far, representing a large increase in activity versus its average volume (3m) of 204,206. There appears to be no confirmed recent news from the company that may explain the sudden and extremely bullish activity in the stock

A month ago, the biopharmaceutical company reported a net loss of ($0.9) million or ($0.15) per share for the first quarter 2016, versus a net loss of ($1.6) million or ($0.27) per share in the same period the prior year

GlobeImmune, which focuses on developing therapeutic products for cancer and infectious diseases based on its proprietary Tarmogen platform, has 5.75M Shares Outstanding and GBIM stock one-year range is from $0.72 and $6.30 per share

*

Smith_&_Wesson_SWHC Sturm_Ruger_&_Co_RGR

Shares of Smith & Wesson Holding Corp. (Nasdaq:SWHC) and Sturm, Ruger & Co. Inc. (NYSE:RGR) climbed on Monday’s trading session, as investors consider that gun sales would increase due to worries that the Orlando night club shooting – where 50 people died and confirmed as the worst mass shooting in U.S. history – could result in tighter gun regulations

SWHC stock is trading in positive territory by 7.81% (or +$1.67) at $23.08 and 6,857,391 shares of the company changed hands so far

Smith & Wesson, which manufactures and sells firearm products in the United States and internationally,  has 55.11M Shares Outstanding and SWHC stock 52-week range is between $14.71 and $30.44 per share

RGR stock is changing hands at $62.62, up $5.21 (or +9.08%) and 1,106,756 of its shares were traded so far

Sturm, Ruger & Co., which designs, manufactures, and sells firearms under the Ruger trademark in the United States, has 18.96M Shares Outstanding and RGR stock one-year range is between $48.10 and $78.09 per share

**

Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at http://galaxystocks.com/disclaimer/